Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels

NCT00083928 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: Å6 subcutaneous injection

Sponsor

Ångstrom Pharmaceuticals